In the future, the fast-developing technologies, such as single-cell RNA-seq, or in vivo/in vitro shRNA and CRISPR screenings, will help us to identify more therapeutic targets in each specific molecular context, accelerating personalized medicine treatment in IDH-mutant gliomas. This evidence concerns the gene IDH2 and glioma.